Senti Biosciences Inc at JMP Securities Life Sciences Conference Transcript
Welcome back. Thanks for joining us. It's my pleasure to introduce Tim Lu from Senti. Thank you so much for joining us.
Yes, thanks so much for having us. So today, I wanted to share what we're building at Senti, which is a platform for designing next-generation cell and gene therapies. We'll be discussing forward-looking statements today.
So Senti on a mission to create next-generation cell and gene therapies powered by our proprietary gene circuit platform. These gene circuits allow us to design more precise control and activity into a variety of cell and gene therapy modalities.
Senti as a company is internally focused on building CAR-NK products for oncology applications, really trying to tackle some of the major outstanding challenges in liquid and solid tumors in this space. We've also engaged with strategic partnership in non-oncology indications. Very excited to say that this week at ASGCT, we'll be revealing a lot of the new data that's coming out with some new
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |